Question-and-Answer Session
Operator
(Operator instructions) Your first question comes from the line of Angela Larson of SFG. Your line is open.
Angela Larson – SFG
Good morning and thanks for taking questions.
John Plachetka
Good morning
Angela Larson – SFG
Good morning. I was hoping you could remind us a little bit about how you booked the Treximet royalty if you booked it on sales or shipment?
Bill Hodges
We can’t hear you. We’re having trouble in the phone here.
Angela Larson – SFG
Okay. I was hoping you could remind us how you booked the Treximet royalty if it’s on sales or shipments, and the timing of the Imitrex generic?
Marty Reese
The question was how we record the Treximet royalty. Angela, we record those on net sales and we do get a report in time to report those – that they are not delayed a quarter or anything like that. They are net sales for the quarter as reported from GSK.
John Plachetka
Angela, what was the question on the Treximet generic?
Angela Larson – SFG
I was wondering if you could give us some color on the timing of the expected Imitrex generics.
John Plachetka
The Imitrex generics?
Angela Larson – SFG
And how will the Treximet campaign be adjusting at that time?
John Plachetka
We have no indication that the introduction of Imitrex generic is going to make any difference on Glaxo’s plan for Treximet, either in terms of their promotional activities or what the else they’re currently doing. The introduction of the generic is so far, as we know, is still expected to happen in December, is that right?
Marty Reese
Like November 2009.
John Plachetka
November or early December and who was that again?
Marty Reese
Dr. Reddy [ph] as I understand will come in late November 2008 and Ranbaxy [ph] – it’s possible that Ranbaxy will come in December of 2008.
John Plachetka
Okay. It’s speculation that he’ll actually show up.
Angela Larson – SFG
Okay, great. Thank you very much.
John Plachetka
Sure. Thanks, Angela.
Operator
Our next question comes from Ken Trbovich of RBC Capital Market. Your line is open.
Ken Trbovich – RBC Capital Market
Yes, John, I was looking at the run rate for Treximet and I just wanted to run through the numbers whether you make sure you are on the right page, and get some insights in the commercial milestones that you might also earn on Treximet? Looking at the numbers, it looks like that you guys are approaching the $100 million run rate on Treximet at this point. Is there a sense for what magnitude increase we need to see for the first commercial milestone to be triggered?
- To read the full transcript on Seeking Alpha, click here »
